Sarcopenia in the elderly: Basic and clinical issues

Wang, Cuiying; Bai, Li

doi:10.1111/j.1447-0594.2012.00851.x

Cited by 144 publications

(117 citation statements)

References 89 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…Regarding comparison of baseline characteristics between the PMI-H and PMI-L groups, ECOG-PS and BMI were identified to be significant factors. DSMM is associated with disability, functional decline, poorer nutritional status and frailty, which may lead to poorer PS and lower BMI (13,14). However, aging was not identified to be a significant factor in the present study.…”

Section: Discussioncontrasting

confidence: 63%

“…Sarcopenia, defined as decreased skeletal muscle mass (DSMM) and muscle strength, has become a relevant clinical feature for understanding the effects of aging on clinical outcomes (13). Sarcopenia is a commonly observed disorder in aged populations and is associated with disability, functional decline and frailty (13,14). Age-associated sarcopenia is defined as primary sarcopenia, whilst advanced malignancies, as well as chronic inflammatory diseases including renal, heart and liver diseases, can be the causes of secondary sarcopenia (12)(13)(14)(15)(16).…”

Section: Effect Of Pretreatment Psoas Muscle Mass On Survival For Patmentioning

confidence: 99%

See 1 more Smart Citation

Effect of pretreatment psoas muscle mass on survival for patients with unresectable pancreatic cancer undergoing systemic chemotherapy

et al. 2017

View full text Add to dashboard Cite

Abstract. To the best of our knowledge, there are few previous studies that have investigated the effect of decreased skeletal muscle mass (DSMM) on survival in patients with unresectable advanced pancreatic cancer (APC) who are undergoing systemic chemotherapy. Thus, the present study aimed to investigate the impact of DSMM, as determined by the psoas muscle index (PMI) following computed tomography and prior to systemic chemotherapy, on the outcomes of patients with unresectable APC (n=61). The primary endpoint used was the overall survival (OS) rate. The OS rates in the PMI-High group (exceeds the median PMI value in each gender) were retrospectively compared with those in the PMI-Low group (below the median PMI value in each gender), and factors associated with OS were investigated using univariate and multivariate analyses. The study cohort included 31 male and 30 female patients with a median age of 72 years, 13 of whom were stage IVA, and 48 were stage IVB. ). The proportion of patients with performance status 0 in the PMI-High group was significantly high, compared with that in the PMI-Low group [83.3% (25/30) vs. 58.1% (18/31); P=0.0486]. Body mass index in the PMI-High group was significantly higher compared with that in the PMI-Low group (P=0.0154). The 1-year cumulative survival rate was 43.3% in the PMI-High group and 12.9% in the PMI-Low group (P=0.0027). Following multivariate analysis, PMI (P=0.0036), prothrombin time (P=0.0044) and carbohydrate antigen 19-9 (P= 0.0451) were identified to be significant predictors of OS. In conclusion, DSMM, as determined by the PMI, could be a significant predictor of prognosis in patients with unresectable APC who are receiving systemic chemotherapy.

show abstract

Section: Discussioncontrasting

confidence: 63%

Section: Effect Of Pretreatment Psoas Muscle Mass On Survival For Patmentioning

confidence: 99%

Effect of pretreatment psoas muscle mass on survival for patients with unresectable pancreatic cancer undergoing systemic chemotherapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…[1] Diabetes mellitus (DM) is a metabolic disorder which adversely affects the quality of life and life expectancy of elderly population. [2] According to the data from the World Health Organization (WHO), 2.1% of the world's population is diabetic, and the incidence and prevalence have been on the rise with advanced age.…”

mentioning

confidence: 99%

The effect of blood glucose regulation on sarcopenia parameters in obese and diabetic patients

Öztürk

Türkbeyler

Demir

et al. 2017

Turk J Phys Med Rehab

View full text Add to dashboard Cite

The effect of blood glucose regulation on sarcopenia parameters in obese and diabetic patients. Turk J Phys Med Rehab 2018;64(1):72-79. ABSTRACTObjectives: This study aims to evaluate the effect of blood glucose regulation on sarcopenia parameters in sarcopenic, obese, and poorlyregulated diabetic patients. Patients and methods:Between June 2013 and December 2013, a total of 147 patients (64 males, 83 females; mean age 70.3±6.3 years; range, 60 to 90 years) who were diagnosed with sarcopenia according to the European Working Group on Sarcopenia in Older People (EWGSOP) criteria were included in the study. All patients were obese with a body mass index (BMI) of >30 kg/m 2 and their glycated hemoglobin (HbA1c) levels were above 8%. Sarcopenia parameters including the gait speed, muscle strength, muscle mass, and handgrip strength were assessed. After a six-month treatment period, the patients were divided into two groups according to their HbA1c levels as having <8% or >8%. Sarcopenia parameters were evaluated before and after receiving treatment. Results:The mean disease duration was 16±6.2 years. Sixty patients were found to have a HbA1c level of <8% and 45 patients with a HbA1c level of ≥8% at sixth months of follow-up. In better regulated group, sarcopenia parameters such as gait speed, muscle mass, and handgrip strength improved; however, only the change in the muscle mass was found to be statistically significant (p=0.041). There was no significant change in the parameters of sarcopenia in the patient group with a HbA1c level ≥8%. A negative correlation was found between the muscle mass and HbA1c levels in good-and poorly-regulated groups (p=0.039 r:-0.327 and p=0.044 r:-0.183, respectively). Conclusion:Our study demonstrates that lowering HbA1c levels may have positive effects on the muscle mass even in diabetic and sarcopenic obese elderly individuals.

show abstract

“…By contrast, sarcopenia has become a relevant clinical feature for understanding the effects of aging on clinical outcomes (19). Sarcopenia is a commonly observed disorder in aged populations and is associated with disability, functional decline and frailty (19,20). Generally, skeletal muscle mass is regulated depending on the balance between protein synthesis and protein breakdown (21).…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy

et al. 2017

View full text Add to dashboard Cite

Abstract. The present study aimed to examine the impact of sarcopenia, defined as low muscle mass on computed tomography (CT), prior to sorafenib therapy on the clinical outcomes of patients with hepatocellular carcinoma (HCC) receiving sorafenib therapy. In total, 232 patients with unresectable HCC (median age, 72 years) were analyzed, and the extent of sarcopenia was assessed using CT. Cross-sectional areas (cm 2 ) of the skeletal muscles at the third lumbar vertebra level were determined by manual outlining on the CT images. The cross-sectional areas were normalized for height [skeletal rates, progression-free survival (PFS) rates and best treatment response of the sarcopenia group were retrospectively compared with those of the non-sarcopenia group, and the factors associated with OS and PFS were examined. Sarcopenia was observed in 151 patients (65.1%). There were 165 patients with Child-Pugh A and 67 with Child-Pugh B cirrhosis. In the sarcopenia group, the median treatment duration was 66 days, whereas in the non-sarcopenia group it was 103 days (P=0.001). The median OS time was 174 days in the sarcopenia group and 454 days in the non-sarcopenia group (P<0.0001). The median PFS was 77 days in the sarcopenia group and 106 days in the non-sarcopenia group (P=0.0131). Multivariate analysis identified sarcopenia to be an independent predictor of OS (hazard ratio, 0.365; P<0.0001). The objective response rate and disease control rate in the sarcopenia group were significantly lower, compared with those in the non-sarcopenia group (P=0.0146 and P=0.0151, respectively). In conclusion, sarcopenia may be an indicator of poor clinical course in patients with HCC receiving sorafenib. IntroductionHepatocellular carcinoma (HCC) is one of the major causes of cancer-associated mortality worldwide, accounting for 5.7% of all newly diagnosed malignancies (1-5). The annual incidence rates of HCC are the highest in East Asia and Sub-Saharan Africa, where >80% of all known cases develop (1-5). Advances in treatments for HCC during the last few decades markedly improved the prognosis of the disease (1,2,4,5). However, a curative therapy such as surgical resection may be applied to a limited number (<20%) of patients with HCC (5,6). Sorafenib is a multi-kinase inhibitor that suppresses cancer growth and cell proliferation (7,8). Two pivotal randomized phase III studies, namely the Sorafenib HCC Assessment Randomized Protocol study (7)

show abstract

Sarcopenia in the elderly: Basic and clinical issues

Cited by 144 publications

References 89 publications

Effect of pretreatment psoas muscle mass on survival for patients with unresectable pancreatic cancer undergoing systemic chemotherapy

Effect of pretreatment psoas muscle mass on survival for patients with unresectable pancreatic cancer undergoing systemic chemotherapy

The effect of blood glucose regulation on sarcopenia parameters in obese and diabetic patients

Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy

Contact Info

Product

Resources

About